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ABSTRACT
Nowadays, bisphosphonates are considered the drugs of choice for the treatment of several bone disorders.
Their exact mechanism of action is not clear but recently it has been reported that the aminobisphosphonates
inhibit cholesterol biosynthesis and that this might be relevant for their actions on bone osteoclasts. The study
includes 87 postmenopausal women with moderate to severe osteoporosis. The patients were randomly assigned
to intravenous (iv) infusion of 50 mg of the aminobisphosphonate Neridronate dissolved in 100 ml of saline
solution every 2 months for a year (44 patients). The remaining 43 served as controls. At the time of each
infusion blood samples were obtained for the evaluation of total cholesterol, triglycerides, high-density
lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-I (Apo
A-I), apolipoprotein B (Apo B), and total and bone alkaline phosphatase (AP). Free deoxypyridinoline (f-DPD)
was measured in fasting urine specimens. In the control group no significant changes were observed throughout
the study period for any of the biochemical variables. In the Neridronate-treated patients both bone AP and
f-DPD excretion fell significantly by 15–20%. In these patients serum total cholesterol and serum triglycerides
showed marginal decreases, which were occasionally significant. LDL-C and Apo B fell by 5–6% and these
changes were statistically significant at most time points. Apo A-I and HDL-C rose progressively with time. At
the 12th month, HDL-C rose 17–18% (pF 0.0001) above the baseline values. Similar findings were obtained in
four postmenopausal women given high iv doses of Pamidronate or Alendronate. In conclusion aminobispho-
phonates, at least when given iv, induce remarkable and unexpected effects on lipid metabolism with a final
profile that might be clinically relevant. (J Bone Miner Res 2000;15:599–604)
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INTRODUCTION
BISPHOSPHONATES AREa class of compounds resistant tometabolic degradation that have high affinity for bone
mineral and the ability to inhibit osteoclast-mediated bone
resorption.(1) These properties have made several bisphospho-
nates the drugs of choice for the treatment of several bone
disorders such as Paget’s disease, tumor osteolysis, and
osteoporosis.(1–3) The bisphosphonates are taken up by
several cells, and this is associated with a variety of
intracellular effects, but the exact molecular mechanism of
action has not been fully elucidated. Recently, it has been
reported that several bisphosphonates inhibit squalene syn-
thesis and cholesterol biosynthesis.(4) This effect can be
observed both in vitro and ex vivo only with the more potent
nitrogen-containing bisphosphonates and it appears to ex-
plain the osteoclast and macrophage apoptosis associated
with the exposure of these cells to aminobisphosphonates.(5)
Other bisphosphonates, not containing amino groups such as
clodronate and etidronate do not interfere with sterol biosyn-
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thesis and they are metabolized to a cytotoxic analogue of
adenosine triphosphate (ATP), leading to target cell death.(4,6)
On the basis of these new findings on the metabolic
activities of aminobisphosphonates we decided to investi-
gate the effect on lipid metabolism during an ongoing phase
2 clinical trial on the skeletal effects of intravenous (iv)
Neridronate (Abiogen, Pisa, Italy). This is an aminobisphos-
phonate that has been used in patients with Paget’s disease
and malignant hypercalcemia and that is structurally very
similar to Pamidronate (Novartis, Switzerland) and Alendro-
nate (MSD, USA), with the hydroxyl-side chain being




The study includes 87 postmenopausal women aged
53–72 years, who had a lumbar spine bone mineral density
below 2 SD of the mean values of normal premenopausal
women. None of the recruited patients had taken androgen,
estrogen, calcitonin, bisphosphonates, fluoride, pharmaco-
logic doses of vitamin D, or lipid-lowering drugs within the
previous 12 months. Nineteen patients were on hypotensive
drugs including thiazide diuretics, which were used most
often, but the dosage had been stable for at least 6 months
and it did not change during the study follow-up. Three
months before entering the study all women were instructed
to keep to their usual diet but to take 500 mg calcium
supplements if their calcium intake was lower than 1000
mg/day. Seven patients, in whom serum 25-hydroxy-vitamin
D concentration was lower than 10 ng/ml, also were given
50,000–100,000 U of oral vitamin D in 2–4 doses over 2–4
weeks.
Forty-four of the patients were randomly assigned iv
infusion of 50 mg Neridronate dissolved in 100 ml of saline.
The remaining 43 served as controls and were given a saline
infusion only in the first month. Originally,we decided to
evaluate the lipid profile occasionally only after the first
infusion, but an interim analysis of the safety biochemical
data of the first 13 patients within 6–8 weeks led us to
modify the original protocol by including the lipid measure-
ments for at least a year.
All women gave written informed consent to their partici-
pation in the study, in accordance with the ethical principles
stated in the Declaration of Helsinky. The research protocol
and its amendments were approved by our local Ethic
Committee.
Analytic procedures
Fasting blood samples were obtained immediately before
the commencement of treatment (or follow-up for control
subjects) and again at 2, 4, 6, 8, 10, and 12 months. Samples
were stored at280°C while awaiting analysis. Samples
were batched and measured in one assay. Serum cholesterol
was measured enzymatically using the Cobas Integra Roche
analyzer (F. Hoffman-La Roche Ltd. Basilea, Switzerland).
Analytical imprecision was 0.95% at a level of 3.87
mmol/liter and 0.96% at 9.49 mmol/liter. Serum triglycer-
ides were assayed using the glyceryl dehydrogenase reaction
after enzymatic hydrolysis of the glycerides on the Cobas
Integra Roche analyzer. Analytical imprecision was 1.4% at
a level of 1.49 mmol/liter and 1.5% at 5.19 mmol/liter.
High-density lipoprotein cholesterol (HDL-C) was mea-
ured after precipitation of low-density lipoprotein choles-
terol (LDL-C) and very low density lipoproteins (VLDL)
with polyanions and phosphotungstic acid/magnesium chlo-
ride. The supernatant was assayed enzymatically on the
Cobas Mira S analyzer (F. Hoffman-La Roche Ltd. Basilea,
Switzerland) and had an analytical imprecision of 3.8% at a
concentration of 1.03 mmol/liter per milligrams per deciliter
and 3.75% at 3.98 mmol/liter. LDL-C was calculated using
the Friedewald formula.(9) In none of the specimens were the
triglycerides values greater than 10.33 mmol/liter. Apolipo-
protein A-I (Apo A-I) and apolipoprotein B (Apo B) were
measured on the Behring Nephelometer Analyzer (BNA)
(Behringwerke, Marburg AG, Germany) employing anti-
Apo A-I and anti-Apo B nephelometric antisera (Behring-
werke, Marburg AG, Germany). Results were evaluated by
the logit-log function of light-scattering intensities versus
respective concentrations. The intra-assay and interassay
CVs of Apo A-I and Apo B measurements were less than 3%
and 5%, respectively. The total alkaline phosphatase (AP)
was measured by standard autoanalyzer procedures (Cobas
Integra Roche analyzer. The intra-assay and interassay CVs
were below 1.6%. Serum bone AP by ELISA (Alkphase-B,
Metra Biosystems, Mountain View, CA, U.S.A.). The intra-
assay and interassay CVs were 3.9% and 7.6% respectively.
Free deoxypyridinoline (f-DPD) was assayed in spot fasting
urine samples by ELISA. Intra-assay and interassay CVs
were less than 10%. The data were corrected by the urinary
creatinine concentration measured by a standard colorimet-
ric method.
Statistical analysis
The absolute and percent changes in biochemical markers
of bone turnover and serum lipids were distributed normally.
The significance of the differences from the baseline was
then evaluated by Student’s-test for paired observation and
thep values were adjusted by the Bonferroni test of multiple
comparisons. The comparison of the changes between
treated and control patients was evaluated by analysis of
variance (ANOVA) for repeated measures and then by
Student’st-test for unpaired observation (SPSS 8.0 by SPSS
Inc, Chicago, IL, U.S.A.).
RESULTS
The baseline characteristics of the women in the Neridro-
nate group and of the control group were similar and never
statistically different (Table 1). All patients completed the
12-month study; they attended to the investigation controls
diligently, did not modify their diet, and were not given other
drugs that were able to interfere with lipid and bone
metabolism. The distribution of concomitant therapies known
to affect lipid profile was similar in the Neridronate group
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and in the control group. Thiazides were taken by nine
patients of both groups and angiotensin converting enzyme
inhibitors were taken by five patients of the Neridronate
group and by four patients of the control group. The physical
activity and the mean body weight did not change during the
study period.
In the control group the biochemical profile did not
change (Table 2; Figs. 1 and 2). As compared with the
control subjects the Neridronate group had a statistically
significant decrease in bone AP (Fig. 3). Serum concentra-
tion of bone AP decreased during the first 4 months
(218%6 22% SD) and remained suppressed thereafter. The
changes in the urinary excretion of f-DPD were somewhat
more erratic. In the 12th month the changes were significant
only in absolute terms.
Mean serum cholesterol and serum triglycerides slightly
decreased in the Neridronate group, but the changes with
respect to the baseline reached statistical significance only
occasionally either in absolute or fractional terms (Table 2;
FIG. 1. Percent changes in serum total cholesterol and
triglycerides in Neridronate-treated (closed circles) and
control patients (open circles). The symbols (*p , 0.05;
†p , 0.01) over the closed circles indicate the statistical
significance of the changes versus baseline in the Neridro-
nate patients (Student’st-test for paired observation) and
those over the open circles (control patients) indicate the
between-group differences (ANOVA for repeated mea-
sures).
FIG. 2. Percent changes in serum lipoproteins in Neridro-
nate-treated (closed circles) and control patients (open
circles). The symbols (*p , 0.05; †p , 0.01; ‡p , 0.001)
over the closed circles indicate the statistical significance of
the changes versus baseline in the Neridronate patients
(Student’st-test for paired observation) and those over the
open circles (control patients) indicate the between-group
differences (ANOVA for repeated measures).
TABLE 1. BASELINE CHARACTERISTICS OF THEPATIENTS BY
GROUP(MEAN 6 SE) INCLUDING BODY MASS INDEX
(BMI, BODY WEIGHT/HEIGHT, KG/M2), SERUM TOTAL AP,
BONEAP, AND URINARY EXCRETION OFf-DPD
Neridronate Controls
No. 44 43
Age (years) 62.546 1.44 63.306 1.35
Years since menopause (ysm) 16.276 1.64 15.536 1.43
Body weight (kg) 61.616 1.50 62.096 1.67
Height (cm) 1.606 0.01 1.596 0.01
BMI (kg/m2) 24.116 0.54 24.886 0.91
Total AP U/l (32-122) 65.636 3.36 62.376 3.02
Bone AP U/l (12-43) 15.16 0.83 13.146 0.81
f-DPD nM/mM Creat (3.0–7.4) 10.536 1.00 9.896 0.70
BMI, body mass index.
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Fig. 1). Serum LDL-C decreased in the Neridronate-treated
patients within 2 months by 4% and the difference was
statistically significant at a few of the time points (Table 2;
Fig. 2). Serum Apo B decreased also in the treated group by
6% and the changes paralleled those of LDL-C (Fig. 2).
Serum HDL-C progressively rose during Neridronate therapy,
from 14% (p , 0.05) after 2 months to117–18% (p ,
0.0001) in the 12th month. Serum Apo A-I also rose
significantly at most time points in treated patients. The
HDL-C/LDL-C ratio rose progressively up to124% in the
12th month of Neridronate therapy. Significant increases in
Apo A-I/Apo B ratio (Fig. 2) and significant decreases of
total cholesterol/HDL-C (Table 2) also were noted in treated
patients
DISCUSSION
Therapy with Neridronate resulted in significant reduction
in serum concentration of LDL-C and Apo B and in
remarkable increases in Apo A-I and HDL-C. The latter was
still rising in the 12th month of observation. Similar trends
were observed within 2 months in four patients (data not
shown) given three consecutive daily doses of 60 mg
Pamidronate iv (Aredia, Novartis, Italy; three patients) or of
7.5 mg Alendronate (Istituto Gentili, Italy; one patient),
which are two aminobisphosphonates that structurally are
strictly related to Neridronate. This indicates that the effect
on lipoproteins pertains to all aminobisphosphonates. The
lipid profile also was evaluated in 13 of the patients within
1–8 weeks after the first iv infusion of Neridronate as part of
the routine safety assessment. In the six blood samples
obtained in the fourth to sixth week, HDL-C was consis-
tently increased. Actually, it also was this observation that
led us to modify the research protocol and to keep serum
aliquots for the lipid measurement.
The effects on the lipid profile of iv Neridronate appears to
be cumulative for HDL-C lasting for at least 2 months after
each dosing for all lipoproteins. This also was unexpected.
For their pharmacodynamic features, bone cells have been
considered the only possible target of bisphosphonates. In
fact, these compounds concentrate at pharmacologically
relevant concentrations only at the bone surfaces undergoing
an active process of remodeling and the blood concentration
achieved after oral administration is considered quite insuffi-
cient to lead to any pharmacologic effect on other cells (e.g.,
liver) involved in lipid metabolism.(10) Based on these
assumptions when bisphosphonates are administered only
iv, the blood concentrations rise high enough to interfere
with cells that are different from those of the bone tissue,
even though only with a very short lag time. In this study we
have shown that the effects on lipid metabolism of amino-
bisphosphonates are long lasting despite the short half-life of
both circulating bisphosphonates and circulating lipopro-
teins.(1,11)This suggests that the metabolic effects of amino-
FIG. 3. Percent changes in
serum total AP, bone AP, and
f-DPD in Neridronate-treated
(closed circles) and control
patients (open circles). The
symbols (*p , 0.05; †p ,
0.01; ‡p , 0.001) over the
closed circles indicate the
statistical significance of the
changes versus baseline in
the Neridronate patients
(Student’s t-test for paired
observation) and those over
the open circles (control pa-
tients) indicate the between-
group differences (ANOVA
for repeated measures).
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bisphosphonates might not be attributed exclusively to the
simple inhibition of enzymes involved in cholesterol synthe-
sis.(4,5)
The changes in circulating lipoproteins are not accompa-
nied by relevant changes in total serum cholesterol and in
serum triglycerides and this might explain why the remark-
able effects on lipid profile observed here have never been
detected in previous studies, within the routine safety
assessment, which rarely include the evaluation of circulat-
ing lipoproteins. We also are unaware of any such findings in
animal studies, even though for some of them (e.g., Alendro-
nate) a thorough investigation of lipid profile was not
included (Dr. Gideon Rodan, personal communication).
Given the knowledge of the mechanism of action of
bisphosphonates, we are unable to explain the observed
pattern of changes in lipoproteins, which basically consists
in a molar shift in circulating cholesterol from LDL to HDL
forms. The decrease in serum LDL-C and in serum Apo B is
lower than that observed during hormone replacement
therapy in postmenopausal women or during statin adminis-
tration.(12–15) However, the magnitude of the increases in
serum HDL-C and Apo A-I and the HDL/LDL-C ratio after
1 year of intermittent iv Neridronate are clinically relevant
and apparently favorable. The results of this study indicate
that aminobisphosphonates given iv may interfere with lipid
metabolism. This finding has clinical implications because
some iv aminobisphosphonates (e.g., Pamidronate) are used
extensively for the treatment of Paget’s disease and for bone
malignancies and others (e.g., Ibandronate) are expected to
be registered with the iv intermittent formulation for the
treatment of postmenopausal osteoporosis.
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